Phase 2 AMG 714 in Rheumatoid Arthritis
NCT00433875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2007-12-28
Summary
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.
Conditions
Interventions
- DRUG
-
AMG 714
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-12-31
More Related Trials
-
Safety and Efficacy of AMG 827 in Subjects With RA
NCT01059448 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis
NCT00771030 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
INCB047986 in Rheumatoid Arthritis
NCT02151474 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
NCT06087406 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
NCT01408602 ·Status: UNKNOWN ·Phase: PHASE2
-
A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
NCT00038298 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
NCT01636817 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of LY3462817 in Participants With Rheumatoid Arthritis
NCT04634253 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-Term Assessment of Safety and Physical Function With AMG 108 in RA
NCT00369473 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
NCT02744755 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
NCT00814307 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
NCT01878123 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
NCT00034203 ·Status: COMPLETED ·Phase: PHASE2
-
A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
NCT00293826 ·Status: COMPLETED ·Phase: PHASE2
-
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
NCT00083759 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of SPY072 in Rheumatic Disease
NCT07148414 ·Status: RECRUITING ·Phase: PHASE2
-
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
NCT00853385 ·Status: COMPLETED ·Phase: PHASE3
-
Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients
NCT03254966 ·Status: COMPLETED ·Phase: PHASE2
-
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
NCT00847613 ·Status: COMPLETED ·Phase: PHASE3
-
A Rheumatoid Arthritis Study in Participants
NCT01202760 ·Status: COMPLETED ·Phase: PHASE3
-
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
NCT00950989 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
NCT01636843 ·Status: TERMINATED ·Phase: PHASE2